A 1001 by 11 data matrix of a contingency table processed from the FDA Adverse Event Reporting System (FAERS) database. This dataset covers a specific period from Q1 2021 to Q4 2023.
Details
A 1001 by 11 data matrix of a contingency table from the FDA Adverse Event Reporting System (FAERS) database, covering a specified period from Q1 2021 to Q4 2023.
The 1000 rows correspond to the AEs with the highest overall frequency (row marginals) reported during the period and 1 row for Other AEs. The reported AEs - "Off label use" and "Drug ineffective" have been excluded.
The dataset includes the following 10 columns: Clonazepam, Dexmedetomidine, Diazepam, Diphenhydramine, Doxepin, Lorazepam, Midazolam, Mirtazapine, Nitrazepam, Temazepam, and an Other column.
The marginal totals for each column are as follows: Clonazepam: 110,453, Dexmedetomidine: 4,262, Diazepam: 74,859 Diphenhydramine: 134,65, Doxepin: 11,795, Lorazepam: 101,969 Midazolam: 26,264, Mirtazapine: 54,273, Nitrazepam: 3,473, Temazepam: 20,523, Other: 77,487,518
Also refer to supplementary material of: Ding, Y., Markatou, M., & Ball, R. (2020). An evaluation of statistical approaches to postmarketing surveillance. Statistics in Medicine, 39(7), 845-874
for the data generation process. The quarterly files can be found in https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
Examples
data(sedative1000)
head(sedative1000)
#> Clonazepam Dexmedetomidine Diazepam Diphenhydramine
#> Pain 781 16 617 1963
#> Fatigue 1014 7 481 2074
#> Nausea 593 5 630 1532
#> Arthralgia 454 0 229 1190
#> Condition aggravated 462 27 601 708
#> Dyspnoea 1412 7 532 611
#> Doxepin Lorazepam Midazolam Mirtazapine Nitrazepam
#> Pain 194 427 195 212 11
#> Fatigue 89 1729 37 526 37
#> Nausea 38 842 228 453 13
#> Arthralgia 62 336 38 375 7
#> Condition aggravated 35 411 181 250 14
#> Dyspnoea 40 824 115 341 27
#> Temazepam Other
#> Pain 397 1075677
#> Fatigue 363 1013681
#> Nausea 42 758316
#> Arthralgia 27 688506
#> Condition aggravated 70 678843
#> Dyspnoea 16 675191